Healthcare - Biotechnology - NASDAQ - US
$ 6.32
-7.2 %
$ 106 M
Market Cap
-9.72
P/E
CASH FLOW STATEMENT
-11.2 M
OPERATING CASH FLOW
-543 K
INVESTING CASH FLOW
38.4 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Coya Therapeutics, Inc.
| Net Income | -7.99 M |
| Depreciation & Amortization | 27.4 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 872 K |
| Change in Working Capital | -4.64 M |
| Others | -4.4 M |
| Free Cash Flow | -11.2 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|
| OPERATING CASH FLOW | ||||
| Net Income | (8.0) | (12.2) | (4.9) | (0.7) |
| Depreciation & Amortization | 27.4 K | 27.4 K | 16.1 K | 0 |
| Deferred Income Tax | 0 | 0 | 0.4 | 0 |
| Stock Based Compensation | 0.9 | 0.2 | 0.2 | 0 |
| Other Operating Activities | 0.5 | 4.0 | (0.4) | 0.2 |
| Change in Working Capital | (4.6) | 0.8 | 0.7 | 78 K |
| Cash From Operations | (11.2) | (7.2) | (3.9) | (0.4) |
| INVESTING CASH FLOW | ||||
| Capital Expenditures | 0 | 0 | (0.1) | 0 |
| Other Items | (0.5) | (0.5) | 0 | 0 |
| Cash From Investing Activities | (0.5) | (0.5) | (0.1) | 0 |
| FINANCING CASH FLOW | ||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 10.5 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 89.9 K | (1.1) | (0.3) | 9.1 |
| Cash From Financing Activities | 38.4 | 9.4 | (0.3) | 9.1 |
| CHANGE IN CASH | ||||
| Net Change In Cash | 26.7 | 1.6 | (4.4) | 8.7 |
| FREE CASH FLOW | ||||
| Free Cash Flow | (11.2) | (7.2) | (4.0) | (0.4) |